A renaissance for SRC
The DOI matches its Crossref record; 117 of the 117 references it cites were found in a registry or an index.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“This suggests that SRC activation may also be a dominant feature in CRC, which is supported by the observation that SRC activation was documented in > 80% of CRC [17].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [17]
In the citing paper
“In response signaling from a variety of RTKs (including EGFR, HER2, HER4, PDGFR, VEGFR, FGFR4, GPCR, C-MET, IL-4/IL13/IL-13Rα2, IL-6ST/IL-6R/IL-11R), SRC has been reported to mediate diverse cell signaling pathways including RAS/MAPK (proliferation), PI3K/AKT (survival), FAK (adhesion/migration/EMT), and STAT3 (angiogenesis) [17, 49, 50].”
From An integrative gene expression signature analysis identifies CMS4 KRAS-mutated colorectal cancers sensitive to combined MEK and SRC targeted therapy (2022) · cites this paper as [17]
In the citing paper
“Aberrant SRC activation has been associated with a more aggressive phenotype and a worse prognosis in CRC patients [27, 28, 39].”
From Co-targeting SRC overcomes resistance to BRAF inhibitors in colorectal cancer (2025) · cites this paper as [39]
In the citing paper
“The c-src is a non-receptor protein tyrosine kinase with a 60-kD molecular weight.It is a member of a 9-gene family named the Src family kinases (SFKs)”
From The molecular rationale of Src inhibition in colorectal carcinomas (2014) · cites this paper as [1]
Citations
Cites
Integrins: Versatility, modulation, and signaling in cell adhesion
Hynes, R. O. (1992) · Cell · doi:10.1016/0092-8674(92)90115-s · Cited by 9,859 · cited 1×
“Focal adhesions are also disassembled during transformation, during which the integrity of these structures is disrupted, permitting increased motilit”
BackgroundCell Migration: A Physically Integrated Molecular Process
Lauffenburger, D. A., & Horwitz, A. F. (1996) · Cell · doi:10.1016/s0092-8674(00)81280-5 · Cited by 3,915 · cited 1×
“This is followed by release of adhesions and retraction of the rear en”
BackgroundGiancotti, F. G., & Ruoslahti, E. (1999) · Science · doi:10.1126/science.285.5430.1028 · Cited by 3,869
Creation of human tumour cells with defined genetic elements
Hahn, W. C., Counter, C. M., Lundberg, A. S., Beijersbergen, R. L., Brooks, M. W., & Weinberg, R. A. (1999) · Nature · doi:10.1038/22780 · Cited by 2,345 · cited 1×
“Although not yet reported for c- SRC , it has been possible to transform human fibroblasts with oncogenes such as HRAS when they are combined with human telomerase reverse transcriptase and the SV40 large T antige”
BackgroundTransforming gene product of Rous sarcoma virus phosphorylates tyrosine
Hunter, T., & Sefton, B. M. (1980) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.77.3.1311 · Cited by 2,332 · cited 1×
“v- src was subsequently shown to encode a tyrosine-specific protein kinas”
BackgroundThe STATs of cancer — new molecular targets come of age
Yu, H., & Jove, R. (2004) · Nature Reviews Cancer · doi:10.1038/nrc1275 · Cited by 2,278 · cited 1×
“STAT3 activation by v-Src has also been shown to contribute to other biological properties of cancer cells, including cell growth and survival, and tumour-cell immune evasio”
BackgroundFOCAL ADHESIONS, CONTRACTILITY, AND SIGNALING
Burridge, K., & Chrzanowska-Wodnicka, M. (1996) · Annual Review of Cell and Developmental Biology · doi:10.1146/annurev.cellbio.12.1.463 · Cited by 1,942 · cited 1×
“Small adhesions can transmit stong forces for rapid movement and ultimately mature into larger focal adhesion”
BackgroundReduced cell motility and enhanced focal adhesion contact formation in cells from FAK-deficient mice
llić, D., Furuta, Y., Kanazawa, S., Takeda, N., Sobue, K., Nakatsuji, N., Nomura, S., Fujimoto, J., Okada, M., Yamamoto, T., et al. (1995) · Nature · doi:10.1038/377539a0 · Cited by 1,830
E-cadherin-mediated cell-cell adhesion prevents invasiveness of human carcinoma cells.
Frixen, U. H., Behrens, J., Sachs, M., Eberle, G., Voss, B., Warda, A., Löchner, D., & Birchmeier, W. (1991) · The Journal of cell biology · doi:10.1083/jcb.113.1.173 · Cited by 1,551 · cited 1×
“Definitive studies in transgenic mice indicate that E-cadherin is an invasion suppresso”
BackgroundA causal role for E-cadherin in the transition from adenoma to carcinoma
Perl, A.-K., Wilgenbus, P., Dahl, U., Semb, H., & Christofori, G. (1998) · Nature · doi:10.1038/32433 · Cited by 1,424 · cited 1×
“and overexpression of E-cadherin can, in fact, counteract the acquisition of the invasive phenotyp”
Background
Cited by
Items 101–200 of 999
Chowdhury, A. K., Watkins, T., Parinandi, N. L., Saatian, B., Kleinberg, M. E., Usatyuk, P. V., & Natarajan, V. (2005) · Journal of Biological Chemistry · doi:10.1074/jbc.m411722200 · Cited by 139
Li, Z., Cai, T., Tian, J., Xie, J. X., Zhao, X., Liu, L., Shapiro, J. I., & Xie, Z. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.013821 · Cited by 151
Integrins and Signal Transduction
Cabodi, S., Stefano, P. D., Leal, M. D. P. C., Tinnirello, A. A., Bisarò, B., Morello, V., Damiano, L., Aramu, S., Repetto, D., Tornillo, G., et al. (2010) · Advances in experimental medicine and biology · doi:10.1007/978-1-4419-6066-5_5 · Cited by 152
Wang, J., Zheng, S., Liu, Y., Zhang, Z., Lin, Z., Li, J., Zhang, G., Wang, X., Li, J., & Chen, P. R. (2016) · Journal of the American Chemical Society · doi:10.1021/jacs.6b08933 · Cited by 142
Jaffe, T., & Schwartz, B. (2008) · International Journal of Cancer · doi:10.1002/ijc.23821 · Cited by 147
“Src kinase is activated by the class I cytokine receptor family, as shown for the prolactin receptor,(42) and is involved in the regulation of cell motility.(43) We used a specific Src kinase inhibitor-”
BackgroundMethodTsai, Y.-L., Ha, D. P., Zhao, H., Carlos, A. J., Wei, S., Pun, T. K., Wu, K., Zandi, E., Kelly, K., & Lee, A. S. (2018) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1714866115 · Cited by 132
“SRC expression and activity, as well as cell-surface expression of ER chaperones, increase as tumor advances (13, 49).”
BackgroundInfluentialA new screening assay for allosteric inhibitors of cSrc
Simard, J. R., Klüter, S., Grütter, C., Getlik, M., Rabiller, M., Rode, H. B., & Rauh, D. (2009) · Nature Chemical Biology · doi:10.1038/nchembio.162 · Cited by 144
Targeting SRC in glioblastoma tumors and brain metastases: Rationale and preclinical studies
Ahluwalia, M. S., de Groot, J., Liu, W., & Gladson, C. L. (2010) · Cancer Letters · doi:10.1016/j.canlet.2010.08.014 · Cited by 139
“Interaction between SRC and these proteins disrupts intramolecular inhibitory interactions within SRC, resulting in its activation [[21, 27, 28]].”
BackgroundDasatinib-induced autophagy is enhanced in combination with temozolomide in glioma
Milano, V., Piao, Y., LaFortune, T., & de Groot, J. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-08-0669 · Cited by 126
“After an initial decrease, there was a time-dependent increase in SRC Y527 phosphorylation reflecting an accumulation of SRC protein with phosphorylation of its negative regulatory tyrosine residue (33).”
BackgroundKalinsky, K. M., Lee, S., Rubin, K. M., Lawrence, D. P., Iafrarte, A. J., Borger, D. R., Margolin, K. A., Leitão, M. M., Tarhini, A. A., Koon, H. B., et al. (2017) · Cancer · doi:10.1002/cncr.30663 · Cited by 128
The Role of Src in Colon Cancer and Its Therapeutic Implications
Chen, J., Elfiky, A. A., Han, M., Chen, C., & Saif, M. W. (2013) · Clinical Colorectal Cancer · doi:10.1016/j.clcc.2013.10.003 · Cited by 141
“These proteins are activated by a number of receptors—including receptors of platelet-derived growth factors, epidermal growth factor, fibroblast growth factor, hepatocyte growth factor, cytokines, and adipokines—and by hyperosmotic stress, They regulate a cascade of downstream targets to control cellular process, cel…”
BackgroundInfluentialSrc Family Kinases as Novel Therapeutic Targets to Treat Breast Cancer Brain Metastases
Zhang, S., Huang, W.-C., Zhang, L., Zhang, C., Lowery, F. J., Ding, Z., Guo, H., Wang, H., Huang, S., Sahin, A. A., et al. (2013) · Cancer Research · doi:10.1158/0008-5472.can-12-1803 · Cited by 125
“The crosstalk between Src signaling and RTKs facilitates RTK-addicted tumor growth (32).”
Serrels, A., Macpherson, I. R. J., Evans, T. R. J., Lee, F. Y., Clark, E. A., Sansom, O. J., Ashton, G. H., Frame, M. C., & Brunton, V. G. (2006) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-06-0382 · Cited by 124
“Src expression is frequently elevated in a number of epithelial tumors, including colon, breast, pancreas, lung, and ovarian, compared with the adjacent normal tissues (2, 3, 5).”
BackgroundBuettner, R., Mesa, T., Vultur, A., Lee, F., & Jove, R. (2008) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-08-0169 · Cited by 123
“Introduction Increased protein levels and kinase activities of Src family kinases (SFK) have been observed in a wide diversity of human cancers, including melanoma, breast, ovarian, and lung cancer (1-7).”
BackgroundSrc: coordinating metabolism in cancer
Pelaz, S. G., & Tabernero, A. (2022) · Oncogene · doi:10.1038/s41388-022-02487-4 · Cited by 138
“Src, one of the best studied oncoproteins, has been shown to regulate these hallmarks that ultimately control the behaviour of transformed cells and contribute to tumour progression and metastasis [2].”
BackgroundDeath‐associated protein kinase (DAPK) and signal transduction: regulation in cancer
Michie, A. M., McCaig, A. M., Nakagawa, R., & Vukovic, M. (2010) · The FEBS Journal · doi:10.1111/j.1742-4658.2009.07414.x · Cited by 121
Src redox regulation: Again in the front line
Giannoni, E., Taddei, M. L., & Chiarugi, P. (2010) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2010.04.025 · Cited by 125
Role of Cannabinoid Receptor CB2 in HER2 Pro-oncogenic Signaling in Breast Cancer
Pérez-Gómez, E., Andradas, C., Blasco-Benito, S., Caffarel, M. M., García-Taboada, E., Villa‐Morales, M., Moreno, E., Hamann, S., Martín-Villar, E., Flores, J. M., et al. (2015) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djv077 · Cited by 135
The Glycolytic Inhibitor 2-Deoxyglucose Activates Multiple Prosurvival Pathways through IGF1R
Zhong, D., Xiong, L., Liu, T., Liu, X., Liu, X., Chen, J., Sun, S.-Y., Khuri, F. R., Zong, Y., Zhou, Q., et al. (2009) · Journal of Biological Chemistry · doi:10.1074/jbc.m109.005280 · Cited by 121
García, A. A., Sill, M. W., Lankes, H. A., Godwin, A. K., Mannel, R. S., Armstrong, D. K., Carolla, R. L., Liepman, M. K., Spirtos, N. M., Fischer, E. G., et al. (2011) · Gynecologic Oncology · doi:10.1016/j.ygyno.2011.10.022 · Cited by 125
“SRC is a component of signaling pathways downstream of many growth factor receptors, including epidermal growth factor receptor (EGFR), vascular endothelial growth factor receptor (VEGFR), and MNNG transforming gene product (c-MET) [4].”
BackgroundBertotti, A., Comoglio, P. M., & Trusolino, L. (2006) · The Journal of Cell Biology · doi:10.1083/jcb.200605114 · Cited by 120
“This notion, together with the established observation that Src can promote anchorage-independent growth when aberrantly activated (Yeatman, 2004), prompted us to investigate whether the signaling contribution of β4 to this process could entail the stimulation of Src.”
BackgroundTsao, A. S., He, D., Saigal, B., Liu, S., Lee, J. J., Bakkannagari, S., Ordóǹez, N. G., Hong, W. K., Wistuba, I. I., & Johnson, F. M. (2007) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-07-0052 · Cited by 126
“domain (Y419 in humans) leads to the unfolding of the tertiary structure of c-Src and exposure of the kinase catalytic site (5, 18).”
BackgroundFyn is an important molecule in cancer pathogenesis and drug resistance
Eliáš, D., & Ditzel, H. J. (2015) · Pharmacological Research · doi:10.1016/j.phrs.2015.08.010 · Cited by 129
Brábek, J., Constancio, S. S., Siesser, P. F., Shin, N.-Y., Pozzi, A., & Hanks, S. K. (2005) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-05-0015 · Cited by 119
Reciprocal Regulation of c-Src and STAT3 in Non-Small Cell Lung Cancer
Byers, L. A., Sen, B., Saigal, B., Diao, L., Wang, J., Nanjundan, M., Cascone, T., Mills, G. B., Heymach, J. V., & Johnson, F. M. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-09-0767 · Cited by 117
Chemical Rescue of a Mutant Enzyme in Living Cells
Qiao, Y., Molina, H., Pandey, A., Zhang, J., & Cole, P. A. (2006) · Science · doi:10.1126/science.1122224 · Cited by 117
The Met pathway: master switch and drug target in cancer progression
Mazzone, M., & Comoglio, P. M. (2006) · The FASEB Journal · doi:10.1096/fj.06-5947rev · Cited by 124
“Because it is commonly activated, but never mutated, in a large number of human cancers and because its mechanisms of activation are now better understood, drug development programs have been able to inhibit Src activity (99).”
BackgroundCUB Domain-Containing Protein 1 Is a Novel Regulator of Anoikis Resistance in Lung Adenocarcinoma
Uekita, T., Jia, L., Narisawa-Saito, M., Yokota, J., Kiyono, T., & Sakai, R. (2007) · Molecular and Cellular Biology · doi:10.1128/mcb.01246-07 · Cited by 117
“The activities of SFKs often correlate with the malignant potential of cancer and poor prognosis (36).”
BackgroundThe Lipid Raft-Anchored Adaptor Protein Cbp Controls the Oncogenic Potential of c-Src
Oneyama, C., Hikita, T., Enya, K., Dobenecker, M.-W., Saito, K., Nada, S., Tarakhovsky, A., & Okada, M. (2008) · Molecular Cell · doi:10.1016/j.molcel.2008.03.026 · Cited by 116
Aurora kinase A mediates epithelial ovarian cancer cell migration and adhesion
Do, T.-V., Xiao, F., Bickel, L. E., Klein-Szanto, A. J., Pathak, H. B., Hua, X., Howe, C., O'Brien, S. W., Maglaty, M., Ecsedy, J. A., et al. (2014) · Oncogene · doi:10.1038/onc.2012.632 · Cited by 115
Yang, S., Banavali, N. K., & Roux, B. (2009) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0808261106 · Cited by 115
Qi, J., Wang, J., Romanyuk, O., & Siu, C.-H. (2006) · Molecular Biology of the Cell · doi:10.1091/mbc.e05-10-0927 · Cited by 115
“The Src family of kinases includes nine members, among which Src has been shown mostly to be involved in the regulation of the cadherin–catenin complex as well as cancer metastasis (Nelson and Nusse, 2004; Yeatman, 2004).”
BackgroundInfluentialLeroy, C., Fialin, C., Sirvent, A., Simon, V., Urbach, S., Poncet, J., Robert, B., Jouin, P., & Roche, S. (2009) · Cancer Research · doi:10.1158/0008-5472.can-08-2354 · Cited by 114
“Accordingly, kinase activation often correlates with protein overexpression (2).”
BackgroundInfluentialProgress towards the development of SH2 domain inhibitors
Kraskouskaya, D., Duodu, E., Arpin, C. C., & Gunning, P. T. (2013) · Chemical Society Reviews · doi:10.1039/c3cs35449k · Cited by 114
Elbediwy, A., Vincent‐Mistiaen, Z. I., & Thompson, B. J. (2016) · BioEssays · doi:10.1002/bies.201600037 · Cited by 122
Src continues aging: current and future clinical directions
Kopetz, S., Shah, A. N., & Gallick, G. E. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-1902 · Cited by 111
Emerging molecular targets in melanoma invasion and metastasis
Orgaz, J. L., & Sanz‐Moreno, V. (2012) · Pigment Cell & Melanoma Research · doi:10.1111/pcmr.12041 · Cited by 127
“Src family kinases are pleiotropic kinases involved in cell migration, adhesion and invasion, as well as proliferation and survival (Yeatman, 2004).”
BackgroundPodoplanin - a small glycoprotein with many faces.
Ugorski, M., Dzięgiel, P., & Suchański, J. (2016) · PubMed Central · Cited by 109
Anticancer therapeutics: “Addictive” targets, multi-targeted drugs, new drug combinations
Broxterman, H. J., & Georgopapadakou, N. H. (2005) · Drug Resistance Updates · doi:10.1016/j.drup.2005.07.002 · Cited by 125
Baselga, J., Cervantes, A., Martinelli, E., Chirivella, I., Hoekman, K., Hurwitz, H. I., Jodrell, D. I., Hamberg, P., Casado, E., Elvin, P., et al. (2010) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-10-0748 · Cited by 109
“Dysregulation of Src has been implicated in numerous tumor types, and is thought to mediate processes important for tumor progression, such as cellular adhesion, migration, survival and proliferation (2).”
BackgroundTyrosine phosphorylation in mitochondria: A new frontier in mitochondrial signaling
Salvi, M., Brunati, A. M., & Toninello, A. (2005) · Free Radical Biology and Medicine · doi:10.1016/j.freeradbiomed.2005.02.006 · Cited by 109
Src tyrosine kinase is crucial for potassium channel function in human pulmonary arteries
Nagaraj, C., Tang, B., Bálint, Z., Wygrecka, M., Hrzenjak, A., Kwapiszewska, G., Stacher, E., Lindenmann, J., Weir, Ε. K., Olschewski, H., et al. (2012) · European Respiratory Journal · doi:10.1183/09031936.00211811 · Cited by 107
“The SH1 domain of the SrcTK contains the phosphorylation site tyr419 which is required for full C-SrcTK activation [5].”
BackgroundTan, M., Li, P., Klos, K. S., Lu, J., Lan, K.-H., Nagata, Y., Fang, D., Jing, T., & Yu, D. (2005) · Cancer Research · doi:10.1158/0008-5472.can-04-2353 · Cited by 106
“The human c-Src proto-oncogene encodes an intracellular tyrosine kinase, pp60 (22, 23).”
BackgroundCai, J., Sun, M., Wu, X., Chen, J., Wang, P., Zong, X., & Ji, M. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.03.013 · Cited by 113
PI3-K/Akt-mediated anoikis resistance of human osteosarcoma cells requires Src activation
Diaz-Montero, C. M., Wygant, J. N., & McIntyre, B. W. (2006) · European Journal of Cancer · doi:10.1016/j.ejca.2006.03.007 · Cited by 105
Cloning and characterization of SARI (suppressor of AP-1, regulated by IFN)
Su, Z.-Z., Lee, S., Emdad, L., Lebdeva, I. V., Gupta, P., Valerie, K. C., Sarkar, D., & Fisher, P. B. (2008) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0807975106 · Cited by 118
“Ras, src, and AP-1 activations are extremely common events in the process of carcinogenesis and SARI would therefore have significant potential to exert broad-spectrum anti-tumor activity (23, 26, 27).”
BackgroundWong, W. K. P., Knowles, J. A., & Morse, J. H. (2005) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2005-0103oc · Cited by 104
“In addition to cell proliferation, c-Src tyrosine kinase regulates cell adhesion, invasion, and motility, which may contribute to tumor progression and metastasis (15).”
BackgroundAnil Kumar, M. S., Ahmad, I., Chhikara, B. S., Tiwari, R. K., Mandal, D., & Parang, K. (2011) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2011.01.047 · Cited by 112
Targeted Inhibition of Src Kinase Signaling Attenuates Pancreatic Tumorigenesis
Nagathihalli, N. S., Smith, J. J., Revetta, F. L., Washington, M. K., & Merchant, N. B. (2010) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-1212 · Cited by 103
Proto-oncogene Src links lipogenesis via lipin-1 to breast cancer malignancy
Song, L., Liu, Z., Hu, H.-H., Yang, Y., Li, T. Y., Lin, Z., Ye, J., Chen, J., Huang, X. X., Liu, D.-T., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-19694-w · Cited by 106
Tan, M., Li, P., Sun, M., Yin, G., & Yu, D. (2005) · Oncogene · doi:10.1038/sj.onc.1209361 · Cited by 119
“Src, an intracellular tyrosine kinase, is a critical component of the multiple signaling pathways that regulate a wide variety of cellular functions (Martin, 2001; Ishizawar and Parsons, 2004; Yeatman, 2004).”
BackgroundOneyama, C., Ikeda, J., Okuzaki, D., Suzuki, K., Kanou, T., Shintani, Y., Morii, E., Okumura, M., Aozasa, K., & Okada, M. (2011) · Oncogene · doi:10.1038/onc.2011.63 · Cited by 113
Das, S., Chakraborty, S., & Basu, A. (2010) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2010.06951.x · Cited by 102
Activity of the multikinase inhibitor dasatinib against ovarian cancer cells
Konecny, G. E., Glas, R., Dering, J., Manivong, K., Qi, J., Finn, R. S., Yang, G. R., Hong, K.-L., Ginther, C., Winterhoff, B. J. N., et al. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605381 · Cited by 104
“In turn, a wide range of Src substrates have been identified that regulate cell growth, adhesion, invasion, and motility (Thomas and Brugge, 1997; Yeatman, 2004).”
BackgroundInfluentialBreast cancer: Current and future endocrine therapies
Palmieri, C., Patten, D. K., Januszewski, A. P., Zucchini, G., & Howell, S. J. (2013) · Molecular and Cellular Endocrinology · doi:10.1016/j.mce.2013.08.001 · Cited by 112
The C terminus of talin links integrins to cell cycle progression
Wang, P., Ballestrem, C., & Streuli, C. H. (2011) · Journal of Cell Biology · doi:10.1083/jcb.201104128 · Cited by 100
“Src phosphorylation was not altered in talin-depleted cells, but this may not be surprising as it remains phosphorylated in FAK MECs and can be activated independently by growth factor receptors (Yeatman, 2004; van Miltenburg et al., 2009).”
Dasatinib: an anti-tumour agent via Src inhibition.
Gnoni, A., Marech, I., Silvestris, N., Vacca, A., & Lorusso, V. (2011) · Current Drug Targets · doi:10.2174/138945011794751591 · Cited by 103
“, the Fyn, Yes, Src, and Lyk, but it also inhibits BCR-ABL, EphA2, platelet derived growth factor receptor (PDGFR), and c-KIT [1].”
BackgroundXu, R., Song, J., Ruze, R., Chen, Y., Yin, X., Wang, C., & Zhao, Y. (2023) · Cell Death and Disease · doi:10.1038/s41419-023-05987-7 · Cited by 108
“Src, a member of nonreceptor tyrosine kinases SFKs, plays a crucial role in malignant progression for various cancers, as overexpression/activation promotes malignancy [43].”
BackgroundSrc inhibitor dasatinib inhibits growth of breast cancer cells by modulating EGFR signaling
Nautiyal, J., Majumder, P., Patel, B. B., Lee, F. Y., & Majumdar, A. P. N. (2009) · Cancer Letters · doi:10.1016/j.canlet.2009.03.035 · Cited by 100
“c-Src regulates several cellular processes that involve cell survival and proliferation [51], and, regulate tumor cell invasion resulting in metastatic spread of the disease [52].”
BackgroundMattila, J., Omelyanchuk, L., Kyttala, S., Turunen, H., & Nokkala, S. (2005) · The International Journal of Developmental Biology · doi:10.1387/ijdb.052006jm · Cited by 100
CUB-domain–containing protein 1 (CDCP1) activates Src to promote melanoma metastasis
Liu, H., Ong, S., Badu-Nkansah, K. A., Schindler, J. W., White, F. M., & Hynes, R. O. (2011) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1017228108 · Cited by 111
Global Impact of Oncogenic Src on a Phosphotyrosine Proteome
Luo, W., Slebos, R. J., Hill, S., Li, M., Brábek, J., Amanchy, R., Chaerkady, R., Pandey, A., Ham, A.-J. L., & Hanks, S. K. (2008) · Journal of Proteome Research · doi:10.1021/pr800187n · Cited by 99
Smolinski, M. P., Bu, Y., Clements, J. L., Gelman, I. H., Hegab, T., Cutler, D. L., Fang, J. W. S., Fetterly, G. J., Kwan, R., Barnett, A., et al. (2018) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.8b00164 · Cited by 98
Singh‐Gupta, V., Zhang, H., Banerjee, S., Kong, D., Raffoul, J. J., Sarkar, F. H., & Hillman, G. G. (2008) · International Journal of Cancer · doi:10.1002/ijc.24015 · Cited by 101
Li, Y., Fu, S.-Y., Wang, L., Wang, F., Wang, N., Cao, Q., Wang, Y., Yang, J., & Wu, C. (2015) · Cancer Letters · doi:10.1016/j.canlet.2015.07.029 · Cited by 95
Invasive Prostate Carcinoma Driven by c-Src and Androgen Receptor Synergy
Cai, H., Babić, I., Wei, X. X., Huang, J., & Witte, O. N. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-1605 · Cited by 100
Targeted Therapies in Triple-Negative Breast Cancer
Marmé, F., & Schneeweiß, A. (2015) · Breast Care · doi:10.1159/000433622 · Cited by 103
Phosphorylation of unique domains of Src family kinases
Amata, I., Maffei, M., & Pons, M. (2014) · Frontiers in Genetics · doi:10.3389/fgene.2014.00181 · Cited by 99
“Among the SFKs, Src is the most studied and the most commonly discussed in the context of cancer (Yeatman, 2004).”
BackgroundInfluentialSrc, a potential target for overcoming trastuzumab resistance in HER2-positive breast carcinoma
Peiró, G., Ortiz-Martínez, F., Gallardo, A., Perez‐Balaguer, A., Sánchez–Payá, J., Ponce, J., Tibau, A., López-Vilaró, L., Escuín, D., Adrover, E., et al. (2014) · British Journal of Cancer · doi:10.1038/bjc.2014.327 · Cited by 106
“Src has a role in signalling and crosstalk between growthpromoting pathways (Yeatman, 2004).”
BackgroundPhosphoregulation of the WAVE regulatory complex and signal integration
Mendoza, M. C. (2013) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2013.01.007 · Cited by 94
“Src phosphorylates many components of focal adhesions to promote actin remodeling and adhesion turnover [61-63].”
BackgroundTian, J., Raffa, F. A., Dai, M., Moamer, A., Khadang, B., Hachim, I. Y., Bakdounes, K., Ali, S., Jean‐Claude, B. J., & Lebrun, J. J. (2018) · British Journal of Cancer · doi:10.1038/s41416-018-0287-3 · Cited by 102
The Unique Domain Forms a Fuzzy Intramolecular Complex in Src Family Kinases
Arbesú, M., Maffei, M., Cordeiro, T. N., Teixeira, J. M. C., Pérez, Y., Bernadó, P., Roche, S., & Pons, M. (2017) · Structure · doi:10.1016/j.str.2017.02.011 · Cited by 96
Schneditz, G., Elias, J. E., Pagano, E., Cader, M. Z., Saveljeva, S., Long, K. R., Mukhopadhyay, S., Arasteh, J. M., Lawley, T. D., Dougan, G., et al. (2019) · Science Signaling · doi:10.1126/scisignal.aau9048 · Cited by 96
“In addition to its long-appreciated role in advanced tumor stages and metastasis (81), Src is also required for early intestinal tumorigenesis caused by APC mutation (66), which may be of particular importance in the tumor-prone epithelium in UC and PSC.”
BackgroundKasahara, K., Nakayama, Y., Kihara, A., Matsuda, D., Ikeda, K., Kuga, T., Fukumoto, Y., Igarashi, Y., & Yamaguchi, N. (2007) · Experimental Cell Research · doi:10.1016/j.yexcr.2007.05.001 · Cited by 93
Malyukova, I. V., Murray, K. F., Zhu, C., Boedeker, E. C., Kane, A. V., Patterson, K., Peterson, J. R., Donowitz, M., & Kovbasnjuk, O. N. (2008) · American Journal of Physiology-Gastrointestinal and Liver Physiology · doi:10.1152/ajpgi.90347.2008 · Cited by 114
“Src contains a SH1 kinase domain, the autophosphorylation site (p-Src-Tyr416) of which is necessary for full activation (33, 82).”
BackgroundNa/K-ATPase Mimetic pNaKtide Peptide Inhibits the Growth of Human Cancer Cells
Li, Z., Zhang, Z., Xie, J. X., Li, X., Tian, J., Cai, T., Cui, H., Ding, H., Shapiro, J. I., & Xie, Z. (2011) · Journal of Biological Chemistry · doi:10.1074/jbc.m110.207597 · Cited by 102
Daud, A. I., Krishnamurthi, S. S., Saleh, M. N., Gitlitz, B. J., Borad, M. J., Gold, P. J., Chiorean, E. G., Springett, G. M., Abbas, R., Agarwal, S., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2378 · Cited by 92
“At the 600mg dose level, 3 of 10 patients had DLTs; grade 3 rash (1) and grade 3 diarrhea (2).”
BackgroundEl‐Karim, S. S. A., Anwar, M. M., Mohamed, N. A., Nasr, T., & Elseginy, S. A. (2015) · Bioorganic Chemistry · doi:10.1016/j.bioorg.2015.08.006 · Cited by 92
Koreckij, T., Nguyen, H., Brown, L. G., Yu, E. Y., Vessella, R. L., & Corey, E. (2009) · British Journal of Cancer · doi:10.1038/sj.bjc.6605178 · Cited by 92
“It is involved in cellular proliferation, survival, motility and angiogenesis (Yeatman, 2004).”
BackgroundOsteoclast motility: Putting the brakes on bone resorption
Novack, D. V., & Faccio, R. (2009) · Ageing Research Reviews · doi:10.1016/j.arr.2009.09.005 · Cited by 99
Lin, C., Lin, C., Chen, K.-H., Wu, J.-C., Huang, S.-H., & Wang, S. (2006) · FEBS Letters · doi:10.1016/j.febslet.2006.04.049 · Cited by 91
High glucose enhances progression of cholangiocarcinoma cells via STAT3 activation
Saengboonmee, C., Seubwai, W., Pairojkul, C., & Wongkham, S. (2016) · Scientific Reports · doi:10.1038/srep18995 · Cited by 92
Antitumor Effects and Biomarkers of Activity of AZD0530, a Src Inhibitor, in Pancreatic Cancer
Rajeshkumar, N. V., Tan, A. C., De Oliveira, E., Womack, C., Wombwell, H., Morgan, S., Warren, M. V., Walker, J., Green, T. P., Jimeno, A., et al. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-3021 · Cited by 90
Src-mediated regulation of E-cadherin and EMT in pancreatic cancer
Nagathihalli, N. S. (2012) · Frontiers in bioscience · doi:10.2741/4037 · Cited by 96
“Hypoxia, a common characteristic of the tumor microenvironment (57, 58), can favor invasive growth and malignant progression by stimulating the Src/STAT3/VEGF pathway which then promotes angiogenesis, a step necessary for the growth of both the primary tumor and distant metastases (22, 59, 60) (Figure 2).”
BackgroundLipid binding by the Unique and SH3 domains of c-Src suggests a new regulatory mechanism
Pérez, Y., Maffei, M., Igea, A., Amata, I., Gairí, M., Nebreda, A. R., Bernadó, P., & Pons, M. (2013) · Scientific Reports · doi:10.1038/srep01295 · Cited by 90
“Phosphatidylinositol (3,4,5)P3 interacts with SH2 domains and modulates PI 3-kinase association with tyrosine-phosphorylated proteins.”
BackgroundInfluentialThiol Redox Transitions in Cell Signaling: a Lesson from N-Acetylcysteine
Parasassi, T., Brunelli, R., Costa, G., De Spirito, M., Krasnowska, E., Lundeberg, T., Pittaluga, E., & Ursini, F. (2010) · The Scientific World JOURNAL · doi:10.1100/tsw.2010.104 · Cited by 90
“This kinase is the product of the first discovered and, possibly, most investigated proto-oncogene, whose multiple functions and regulation mechanisms are still far from being fully elucidated[30].”
BackgroundSmall-molecule-mediated rescue of protein function by an inducible proteolytic shunt
Pratt, M. R., Schwartz, E. C., & Muir, T. W. (2007) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0700816104 · Cited by 89
Src family kinases as mediators of endothelial permeability: effects on inflammation and metastasis
Kim, M. P., Park, S. I., Kopetz, S., & Gallick, G. E. (2009) · Cell and Tissue Research · doi:10.1007/s00441-008-0682-9 · Cited by 89
“Complementing these endeavors, studies of signaling pathways leading to the activation of Src and its closely related homologs in the Src family of kinases (SFKs) have been central toward understanding normal growth-regulatory processes, including proliferation, apoptosis, cell cycle control, angiogenesis, and cell-ce…”
BackgroundIdentification of EDIL3 on extracellular vesicles involved in breast cancer cell invasion
Lee, J., Moon, P., Cho, Y., Kim, Y., Kim, I., Park, H.-Y., & Baek, M. (2015) · Journal of Proteomics · doi:10.1016/j.jprot.2015.10.005 · Cited by 96
Targeted therapies in breast cancer: Where are we now?
Cosimo, S. D., & Baselga, J. M. (2008) · European Journal of Cancer · doi:10.1016/j.ejca.2008.09.026 · Cited by 101
Planas-Silva, M. D., Bruggeman, R. D., Grenko, R. T., & Smith, J. S. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.12.164 · Cited by 94
Regulation of Src Family Kinases during Colorectal Cancer Development and Its Clinical Implications
Jin, W. (2020) · Cancers · doi:10.3390/cancers12051339 · Cited by 86
“The purification of v-Src (pp60src) from Rous sarcoma virus (RSV), which activates the insulin receptor, led to the identification of various Src family kinases (SFKs) [1,2], such as Src, Fyn, Yes, Yrk, Fgr, Hck, Blk, lymphocyte-specific protein tyrosine kinase (Lck), and Lyn.”
BackgroundFu, Y., Yang, G., Zhu, F., Peng, C., Li, W., Li, H., Kim, H.-G., Bode, A. M., Dong, Z., & Dong, Z. (2014) · Cell Death and Disease · doi:10.1038/cddis.2013.509 · Cited by 90
The Src Family of Protein Tyrosine Kinases: A New and Promising Target for Colorectal Cancer Therapy
Lieu, C., & Kopetz, S. (2010) · Clinical Colorectal Cancer · doi:10.3816/ccc.2010.n.012 · Cited by 86
Src oncogene activates MMP‐2 expression via the ERK/Sp1 pathway
Kuo, L., Chang, H., Leu, T., Maa, M., & Hung, W. (2006) · Journal of Cellular Physiology · doi:10.1002/jcp.20616 · Cited by 85
“In addition to promote the proliferation of cancer cells, Src alsoaffects cell adhesion and invasionand has been linked to the development of tumor metastasis (Yeatman, 2004).”
BackgroundSrc in endosomal membranes promotes exosome secretion and tumor progression
Hikita, T., Kuwahara, A., Watanabe, R., Miyata, M., & Oneyama, C. (2019) · Scientific Reports · doi:10.1038/s41598-019-39882-z · Cited by 85
Oh, S. C., Park, Y.-Y., Park, E. S., Lim, J. Y., Kim, S. M., Kim, S.-B., Kim, J., Kim, S. C., Chu, I.-S., Smith, J. J., et al. (2012) · Gut · doi:10.1136/gutjnl-2011-300812 · Cited by 84
“Interestingly, two genes in the NF-kB network are FYN and LYNdpart of SRC tyrosine kinase familydwhose activity are frequently increased and well associated with metastasis potential and poorer outcome in colon cancer.(28) 29 DISCUSSION By analysing gene expression data from colorectal cancer tissues, we identified a…”
BackgroundResultSelf-citationThe Protein Interaction Network of Extracellular Vesicles Derived from Human Colorectal Cancer Cells
Choi, D., Yang, J., Choi, E.-J., Jang, S. C., Park, S., Kim, O. Y., Hwang, D., Kim, K. P., Kim, Y., Kim, S., et al. (2011) · Journal of Proteome Research · doi:10.1021/pr200842h · Cited by 88
Chellappa, K., Jankova, L., Schnabl, J. M., Pan, S., Brelivet, Y., Fung, C. L.-S., Chan, C., Dent, O. F., Clarke, S. J., Robertson, G. R., et al. (2012) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1106799109 · Cited by 84
“c-Src is a nonreceptor tyrosine kinase that is strongly implicated in the development, growth, progression, and metastasis of several human cancers (3).”
BackgroundImamichi, Y., & Menke, A. (2007) · Cells Tissues Organs · doi:10.1159/000101319 · Cited by 84
“Otherwise, various effectors of activated Src have been identified as important regulators of gene expression such as STAT or MAPK-dependent transcription factor [Frame, 2004; Yeatman, 2004; Kuo et al., 2006].”
Background
Metadata
- Authors
- Yeatman, T. J.
- Affiliations
- Moffitt Cancer Center (US)
- Corresponding author
- Yeatman, Timothy J.
- ORCID
- Yeatman, Timothy J.
- Venue
- Nature Reviews Cancer
- Published
- 2004-06-01
- Volume
- 4
- Issue
- 6
- Pages
- 470-480
- ISSN
- 1474-175X (ISSN-L)
- 1474-1768
- OpenAlex
- W2036988959
- Cited by
- 1,113
- References
- 115
- Citations by year
- 2026: 17 · 2025: 21 · 2024: 20 · 2023: 43 · 2022: 43 · 2021: 46 · 2020: 44 · 2019: 39 · 2018: 49 · 2017: 44 · 2016: 69 · 2015: 56 · 2014: 72 · 2013: 79 · 2012: 73
- FWCI
- 5.40
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- www.springer.com/tdm (vor)
- Locations
- Nature reviews. Cancer (publishedVersion)
- PubMed (publishedVersion)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Cancer Research › Cancer Mechanisms and Therapy
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Kinase Regulation and GTPase Signaling
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Mechanisms of cancer metastasis
- Keywords
- Src kinase, non-receptor tyrosine kinase, cancer, metastasis, cell invasion, cell motility, cell proliferation, anticancer agents, tumor progression
- MeSH terms
- Antineoplastic Agents, Cell Division, Humans, Neoplasm Invasiveness, Neoplasm Metastasis, Neoplasms, Neovascularization, Pathologic, Phenotype, Gene Expression Regulation, Neoplastic, Genes, src, Disease Progression
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.